Sight Sciences, Inc. (NASDAQ:SGHT) Insider Jeremy B. Hayden Sells 4,864 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,864 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.52, for a total transaction of $17,121.28. Following the completion of the transaction, the insider now owns 153,823 shares of the company’s stock, valued at approximately $541,456.96. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sight Sciences Price Performance

NASDAQ:SGHT opened at $3.40 on Tuesday. The stock has a 50 day moving average of $3.97 and a two-hundred day moving average of $5.60. Sight Sciences, Inc. has a 12 month low of $3.30 and a 12 month high of $8.45. The firm has a market cap of $172.57 million, a P/E ratio of -3.33 and a beta of 2.57. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. On average, analysts expect that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

A number of large investors have recently modified their holdings of the business. American Century Companies Inc. lifted its stake in shares of Sight Sciences by 31.1% in the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after buying an additional 8,527 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in Sight Sciences by 5.4% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after acquiring an additional 10,000 shares during the last quarter. Rhumbline Advisers lifted its stake in Sight Sciences by 40.1% in the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after purchasing an additional 11,671 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Sight Sciences during the 3rd quarter worth approximately $75,000. Finally, Geode Capital Management LLC grew its position in shares of Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after purchasing an additional 12,709 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SGHT shares. Piper Sandler reiterated a “neutral” rating and issued a $5.50 price objective (down previously from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Lake Street Capital cut Sight Sciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $10.00 to $5.00 in a report on Monday, November 4th. UBS Group assumed coverage on Sight Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $5.50 price objective on the stock. Citigroup reduced their target price on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Sight Sciences currently has an average rating of “Hold” and an average price target of $5.12.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.